



PRIOR AUTHORIZATION REQUEST

Olumiant

Patient Information:

Name:	
Member ID:	
Address:	
City, State, Zip:	
Date of Birth:	

Prescriber Information:

Name:	
NPI:	
Phone Number:	
Fax Number:	
Address:	
City, State, Zip:	

Requested Medication

Rx Name:	
Rx Strength:	
Rx Quantity:	
Rx Frequency:	
Rx Route of Administration:	
Diagnosis and ICD Code:	

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll-free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

SECTION A: Please note that supporting clinical documentation is required for ALL PA requests. Pharmacy prior authorization reviews can be subject to trial with additional medications that are not listed within the criteria. The policies are subject to change based on COMAR requirements, MDH transmittals and updates to treatment guidelines.

- | | | Yes | No |
|---|---|-----|----|
| 1 | Will the requested medication be used in combination with a Biologic or a Targeted Synthetic Disease-Modifying Antirheumatic Drug (DMARD)? Examples of Biologics include but not limited to adalimumab SC products (Humira, biosimilars), Actemra (IV or SC), Cimzia, Cosentyx, Kevzara, Kineret, Orencia (IV or SC), an infliximab product (for example, Remicade, biosimilars), rituximab IV products (Rituxan, biosimilars), Siliq, Stelara (IV or SC), Taltz, Ilumya, Skyrizi, Tremfya, Entyvio, or Simponi (Aria or SC). Examples of Targeted Synthetic DMARD include but not limited to Cibinqo, Rinvoq, Xeljanz/XR, Otezla.
[If yes, no further questions.] | | |

If you have any
questions, call:
1-888-258-8250

Version 07.2025

PRIOR AUTHORIZATION REQUEST

2	<p>Will the requested medication be used in combination with other potent immunosuppressants (for example, azathioprine, cyclosporine)?</p> <p>[Note: This does NOT include the use of methotrexate in combination with the requested medication.]</p> <p>[If yes, no further questions.]</p>	Yes	No
3	<p>Is the patient currently receiving the requested medication?</p> <p>[If no, skip to question 17.]</p>	Yes	No
4	<p>Has the patient been receiving medication samples for the requested medication?</p> <p>[If yes, skip to question 17.]</p>	Yes	No
5	<p>Does the patient have a previously approved prior authorization (PA) on file with the current plan?</p> <p>[Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.]</p> <p>[If no, skip to question 12.]</p>	Yes	No
6	<p>What is the indication or diagnosis?</p> <p><input type="checkbox"/> Rheumatoid arthritis (If checked, go to 13)</p> <p><input type="checkbox"/> Severe alopecia areata (If checked, go to 7)</p> <p><input type="checkbox"/> COVID-19 (Coronavirus disease 2019) [Note: This includes requests for cytokine release syndrome associated with COVID-19] (If checked, no further questions)</p> <p><input type="checkbox"/> All other indications or diagnoses (If checked, no further questions)</p>		
7	<p>Has the patient been established on therapy for at least 4 months?</p> <p>[If no, skip to question 18.]</p>	Yes	No
8	<p>Has the patient experienced a beneficial clinical response, defined as improvement from baseline (prior to initiating Olumiant) in extent and density of scalp hair loss?</p> <p>[If no, no further questions.]</p>	Yes	No
9	<p>Has documentation been submitted to confirm that the patient has had a positive clinical response compared to baseline, as evidenced by an improvement of at least 10% in the SALT score? ACTION REQUIRED: Submit supporting documentation.</p> <p>[If no, no further questions.]</p>	Yes	No
10	<p>Does the patient continue to require systemic therapy for treatment of alopecia areata? [Note: International consensus states that systemic treatment is best discontinued once complete regrowth has been achieved and maintained for 6 months or when regrowth is sufficient to be managed topically.]</p>	Yes	No

**If you have any
questions, call:
1-888-258-8250**

Version 07.2025

PRIOR AUTHORIZATION REQUEST

[If no, no further questions.]

- | | | | |
|----|--|-----|----|
| 11 | Will the patient be using the requested medication in combination with other janus kinase inhibitors [such as, Xeljanz (tofacitinib), Rinvoq (upadacitinib)]?
[No further questions.] | Yes | No |
| 12 | Has documentation been submitted to confirm that the patient has had a clinical response to therapy, compared to baseline? ACTION REQUIRED: Submit supporting documentation.
[If yes, skip to question 17.]
[If no, no further questions.] | Yes | No |
| 13 | Has the patient been on the established therapy for at least 3 months?
[If no, skip to question 29.] | Yes | No |
| 14 | Has the patient experienced a beneficial clinical response when assessed by at least one objective measure?
[Note: Examples of standardized and validated objective measures of disease activity include Clinical Disease Activity Index (CDAI), Disease Activity Score (DAS) 28 using erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), Patient Activity Scale (PAS)-II, Rapid Assessment of Patient Index Data 3 (RAPID-3), and/or Simplified Disease Activity Index (SDAI).]
[If yes, skip to question 16.] | Yes | No |
| 15 | Has the patient experienced an improvement in at least one symptom, such as decreased joint pain, morning stiffness, or fatigue; improved function or activities of daily living; decreased soft tissue swelling in joints or tendon sheaths?
[If no, no further questions.] | Yes | No |
| 16 | Will the patient be using the requested medication in combination with other janus kinase inhibitors [such as, Xeljanz (tofacitinib), Rinvoq (upadacitinib)]?
[No further questions.] | Yes | No |
| 17 | <p>What is the indication or diagnosis?</p> <p><input type="checkbox"/> Rheumatoid arthritis (If checked, go to 29)</p> <p><input type="checkbox"/> Severe alopecia areata (If checked, go to 18)</p> <p><input type="checkbox"/> COVID-19 (Coronavirus disease 2019) [Note: This includes requests for cytokine release syndrome associated with COVID-19] (If checked, no further questions)</p> <p><input type="checkbox"/> All other indications or diagnoses (If checked, no further questions)</p> | | |
| 18 | Is the patient greater than or equal to 18 year(s) of age?
[If no, no further questions.] | Yes | No |
| 19 | Does the patient have a documented diagnosis of severe alopecia areata? | Yes | No |

**If you have any
questions, call:
1-888-258-8250**

Version 07.2025

PRIOR AUTHORIZATION REQUEST

[If no, no further questions.]

20	Has the patient had a current episode of alopecia areata lasting 6 months or greater? [If no, no further questions.]	Yes	No
21	Does the patient have a scalp hair loss of 50% or greater as measured by the Severity of Alopecia Tool (SALT)? [Note: Mild hair loss is 20% or less scalp hair loss, Moderate is 21 to 49% scalp hair loss and Severe is 50 to 100% scalp hair loss.] [If no, no further questions.]	Yes	No
22	Has the patient tried at least TWO systemic therapies for at least 3 months? [Note: Examples of systemic therapies include corticosteroids, methotrexate, and cyclosporine.] [If no, no further questions.]	Yes	No
23	Has the patient tried TWO topical therapies for at least 6 months for alopecia areata? [Note: Examples of topical therapies include fluocinolone acetonide, betamethasone dipropionate, clobetasol propionate, anthralin.] [If no, no further questions.]	Yes	No
24	Has documentation been submitted to confirm that the patient has had an intolerance, contraindication to, or failed treatment of Xeljanz (tofacitinib) for at least 4 months? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
25	Has documentation been provided to confirm that the patient does NOT have hair loss due to androgenetic alopecia, chemotherapy-induced hair loss, or other causes of hair loss other than alopecia areata? ACTION REQUIRED: Submit supporting documentation. [Note: Androgenetic alopecia includes male and female pattern hair loss; other causes of hair loss include trichotillomania, telogen effluvium, and systemic lupus erythematosus.] [If no, no further questions.]	Yes	No
26	Is the requested medication being prescribed by or in consultation with a rheumatologist or a dermatologist? [If no, no further questions.]	Yes	No
27	Does the requested dose exceed the Food and Drug Administration (FDA) approved label dosing for the indication? [If yes, no further questions.]	Yes	No
28	Will the patient be using the requested medication in combination with other janus kinase inhibitors [such as, Xeljanz (tofacitinib), Rinvoq (upadacitinib)]? [No further questions.]	Yes	No

**If you have any
questions, call:
1-888-258-8250**

Version 07.2025

PRIOR AUTHORIZATION REQUEST

29	Is the patient greater than or equal to 18 year(s) of age? [If no, no further questions.]	Yes	No
30	Does the patient have a documented diagnosis of moderately to severely active rheumatoid arthritis? [If no, no further questions.]	Yes	No
31	Has documentation been submitted to confirm that the patient has tried at least TWO conventional synthetic disease- modifying antirheumatic drugs (DMARD) for at least 3 months? ACTION REQUIRED: Submit supporting documentation. [Note: Examples of conventional synthetic DMARDs include, methotrexate, sulfasalazine, hydroxychloroquine, or leflunomide.] [If yes, skip to question 33.]	Yes	No
32	Has documentation been submitted to confirm that the patient has an intolerance to at least TWO DMARD agents (such as, methotrexate, sulfasalazine, hydroxychloroquine, or leflunomide)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
33	Has documentation been submitted to confirm that the patient has had an intolerance, contraindication to, or failed treatment for at least 3 months with at least one tumor necrosis factor inhibitors, Enbrel (etanercept) or an adalimumab product (Hadlima, Yusimry, or adalimumab-adbm)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
34	Has documentation been submitted to confirm that the patient has had an intolerance, contraindication to, or failed treatment for at least 3 months with Xeljanz (tofacitinib)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
35	Is the requested medication being prescribed by or in consultation with a rheumatologist? [If no, no further questions.]	Yes	No
36	Will the patient be using the requested medication in combination with other janus kinase inhibitors [such as, Xeljanz (tofacitinib), Rinvoq (upadacitinib)]?	Yes	No

Please document the diagnoses, symptoms, and/or any other information important to this review:

**If you have any
questions, call:
1-888-258-8250**

Version 07.2025



PRIOR AUTHORIZATION REQUEST

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

If you have any
questions, call:
1-888-258-8250

Version 07.2025